CD8A and non-small cell lung carcinoma: Interestingly, in a cohort of 29 NSCLC (responders: n = 10) treated with three different anti–PD-(L)1 agents (pembrolizumab, nivolumab, and atezolizumab), 80% of NSCLC patients with partial clinical responses presented early proliferative CD8+ T cells, which were both PD-1+ (exhausted) and Ki67+ (in replication) (99).